Stefan Harb

Dr. Stefan Harb

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDirk Von Lewinski
Dirk Von Lewinski
LHLukas Herold
Lukas Herold
EBEva Bachl
Eva Bachl
HBHeiko Bugger
Heiko Bugger
TGTheresa Glantschnig
Theresa Glantschnig
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes in subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria with a real-world cohort of CS patients. Methods and Results: ECLS-SHOCK eligibility criteria were applied to a prospective single-center CS registry (the PREPARE CS registry) consisting of 557 patients who were consecutively admitted to the catheterization laboratory (cath lab) of the Medical University of Graz, Austria, due to CS (SCAI C-E). Overall use of mechanical circulatory support (MCS) in this cohort was 19%. Sixty-nine percent of the entire cohort had MI-related CS, 38% of whom would have met ECLS-SHOCK eligibility criteria, thus representing only 27% of the PREPARE CS registry. Exclusion from the ECLS-SHOCK trial was based on patients with initial lactate values below 3 mmol/L (n = 168; 43.6%), aged over 80 years (n = 65; 16.9%), and with a duration of cardiopulmonary resuscitation (CPR) exceeding 45 min (n = 22; 5.7%). The 30-day mortality of patients of the PREPARE CS registry who met the ECLS-SHOCK eligibility criteria was 57.0%, compared to 48.4% of patients in the ECLS-SHOCK trial. The patients’ baseline characteristics, however, differed considerably with respect to type of infarction, age, and gender. Conclusions: In a real-world cohort of patients with MI-related CS, only 38% of patients met the eligibility criteria of the ECLS-SHOCK trial. Thus, the impact of the use of VA-ECMO on outcome parameters in MI-related CS, as observed in the ECLS-SHOCK trial, may differ in a more heterogeneous real-world CS population of the PREPARE CS registry.

28 October 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
SSSadeek Sidney Kanoun Schnur
Sadeek Sidney Kanoun Schnur
SDSen Devadathan
Sen Devadathan
RMRyan Moran
Ryan Moran
SHStefan Harb
Stefan Harb
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
Zoltán RuzsaZoltán Ruzsa
Zoltán Ruzsa

17 March 2021 in Kardiologie up2date
Verified
Journal Article
Closed access
PDF file
SHStefan Harb
Stefan Harb
Verkalkte Koronarstenosen erfordern Ballondilatation mit hohen Drucken, um Platz für einen Stent zu schaffen. Das geht meist gut, doch kann es auch misslingen: Der Kalk gibt nicht nach, oder es kommt gar zur Ruptur. Es gibt ein neues Werkzeug für die Kardiologen: Die intrakoronare Lithotripsie (IVL) nutzt Schallwellen, um harte Plaque zu lockern. Im Gegensatz zu den anderen Methoden wurden bislang keine Perforationen beschrieben. Publication Date: 17 March 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

1 January 2026 in Case Reports in Cardiology
Verified
Journal Article
Open access
AMAnass Maaroufi
Anass Maaroufi
NVNicolas Verheyen
Nicolas Verheyen
JAJudit Andreka
Judit Andreka
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
SHStefan Harb
Stefan Harb
Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing myocardial hypertrophy, sometimes leading to mid‐cavity obstruction (MCO), which can be underdiagnosed based solely on noninvasive imaging. Case summary: A 52‐year‐old male with exertional dyspnea and chest pain showed apical hypertrophy on echocardiography, with a mid‐cavity gradient of 27 mmHg at rest and 39 mmHg during Valsalva. MRI confirmed nonischemic late gadolinium enhancement. Invasive dual‐catheterization detected a midventricular gradient of 57 mmHg, rising to 73 mmHg postprovocation. Coronary artery disease was excluded. The patient was managed with beta‐blockers, mavacamten, and aerobic training. Discussion: This case highlights the importance of invasive hemodynamic assessment in diagnosing dynamic MCO, which may be underestimated on echocardiography. Provocation testing and simultaneous pressure measurements aid in accurate diagnosis and individualized therapy. Take‐Home Messages: Invasive assessment is crucial for detecting dynamic MCO in HCM. Myosin inhibitors may offer a novel therapeutic option.